Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: March 7, 2024
Reporting Period: The filing announces financial results for the three and twelve months ended December 31, 2023.
Key Financial Metrics
The provided text is a cover sheet for a Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, no specific numerical values for these metrics are available in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms the issuance of a press release containing the results for the period ended December 31, 2023.
Guidance, Outlook, and Risks
Management Commentary: The Company announced a conference call to be held at 8:00 AM ET on March 7, 2024, to discuss the financial results.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" under Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Risks and Contingencies: No specific risks or contingencies are detailed in this cover document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net income, and cash flow figures for the three and twelve months ended December 31, 2023.
- Verify the details of the conference call held on March 7, 2024, for management's outlook and guidance.
- Confirm the trading symbol (HBIO) and exchange (NASDAQ) for current market data.
- Note that the financial data in the press release is not legally "filed" for liability purposes under Section 18 of the Exchange Act.